{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:35:47Z","timestamp":1790818547021,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Health Service of Spain"},{"name":"Instituto de Salud Carlos IIIInstituto de Salud Carlos III (ISCIII)","award":["EC81\/00457"],"award-info":[{"award-number":["EC81\/00457"]}]},{"name":"Instituto de Salud Carlos IIIInstituto de Salud Carlos III (ISCIII)","award":["PI15\/00973"],"award-info":[{"award-number":["PI15\/00973"]}]},{"name":"CRIS Cancer Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.canlet.2018.02.033","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T05:12:56Z","timestamp":1519362776000},"page":"107-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia"],"prefix":"10.1016","volume":"422","author":[{"given":"M.","family":"Vela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Valent\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Balas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-9195","authenticated-orcid":false,"given":"A.","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.02.033_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with Acute Myeloid Leukemia: medical research council AML12 trial","volume":"155","author":"Gibson","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2018.02.033_bib2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2006-07-038299","article-title":"Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia","volume":"110","author":"Nachman","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.canlet.2018.02.033_bib3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.02.033_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2018.02.033_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2005.10.001","article-title":"Human natural killer cell development and biology","volume":"20","author":"Farag","year":"2006","journal-title":"Blood Rev."},{"issue":"9","key":"10.1016\/j.canlet.2018.02.033_bib6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2018.02.033_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.canlet.2018.02.033_bib8","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2018.02.033_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2018.02.033_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/pbc.21955","article-title":"KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors","volume":"53","author":"P\u00e9rez-Mart\u00ednez","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2018.02.033_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.exphem.2012.07.004","article-title":"Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors","volume":"40","author":"P\u00e9rez-Mart\u00ednez","year":"2012","journal-title":"Exp. Hematol."},{"issue":"11","key":"10.1016\/j.canlet.2018.02.033_bib12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/bmt.2012.43","article-title":"Early evaluation of immune reconstitution following allogeneic CD3\/CD19-depleted grafts from alternative donors in childhood acute leukemia","volume":"47","author":"P\u00e9rez-Mart\u00ednez","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.canlet.2018.02.033_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"\u201cNatural\u201d killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","author":"Kiessling","year":"1975","journal-title":"Eur. J. Immunol."},{"issue":"16","key":"10.1016\/j.canlet.2018.02.033_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.2910160204","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity","author":"Herberman","year":"1975","journal-title":"Int J Cancer"},{"issue":"45","key":"10.1016\/j.canlet.2018.02.033_bib15","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1038\/onc.2008.267","article-title":"NK cells and cancer immunosurveillance","volume":"27","author":"Waldhauer","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.02.033_bib16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex\u00a0vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2018.02.033_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fimmu.2015.00230","article-title":"Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies","volume":"6","author":"Pittari","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2018.02.033_bib18","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2018.02.033_bib19","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2018.02.033_bib20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2018.02.033_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","article-title":"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma","volume":"150","author":"Commander","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.canlet.2018.02.033_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/bmt.2013.195","article-title":"A\u00a0clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD)","volume":"49","author":"Gossai","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2018.02.033_bib23","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/blood-2011-08-374710","article-title":"Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"118","author":"Hijiya","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.canlet.2018.02.033_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/08880018.2010.493578","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience","volume":"27","author":"Tavil","year":"2010","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2018.02.033_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.canlet.2018.02.033_bib26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jcyt.2015.07.011","article-title":"A\u00a0phase I\/II trial of interleukin-15\u2013stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors","volume":"17","author":"P\u00e9rez-Mart\u00ednez","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2018.02.033_bib27","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2018 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.02.033_bib28","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1200\/JCO.2011.41.5323","article-title":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia","volume":"30","author":"Inaba","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.02.033_bib29","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Coustan-Smith","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.canlet.2018.02.033_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicenter trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2018.02.033_bib31","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2018.02.033_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.leu.2402761","article-title":"Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experience","volume":"17","author":"Kreyenberg","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.02.033_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.2004.05354.x","article-title":"Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy","volume":"128","author":"Bader","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2018.02.033_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.smim.2014.02.004","article-title":"Natural killer cells in the treatment of high-risk acute leukaemia","volume":"26","author":"Locatelli","year":"2014","journal-title":"Semin. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2018.02.033_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2796.2009.02121.x","article-title":"Natural killer cell-based immunotherapy in cancer: current insights and future prospects","volume":"266","author":"Sutlu","year":"2009","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.canlet.2018.02.033_bib36","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in\u00a0vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.canlet.2018.02.033_bib37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","article-title":"Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation","volume":"143","author":"Shi","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.canlet.2018.02.033_bib38","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.canlet.2018.02.033_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250051","article-title":"Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma","volume":"5","author":"Leivas","year":"2016","journal-title":"Oncoimmunology"},{"issue":"3b","key":"10.1016\/j.canlet.2018.02.033_bib40","first-page":"1861","article-title":"Autologous natural killer cell therapy for human recurrent malignant glioma","volume":"24","author":"Ishikawa","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2018.02.033_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex\u00a0vivo-expanded natural killer cells demonstrate robust proliferation in\u00a0vivo in high-risk relapsed multiple myeloma patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J.\u00a0Immunother."},{"issue":"15","key":"10.1016\/j.canlet.2018.02.033_bib42","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-10-0735","article-title":"Cytotoxicity of activated natural killer cells against pediatric solid tumors","volume":"16","author":"Cho","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2018.02.033_bib43","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2014-07-592881","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell depleted stem celltransplantation","volume":"125","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canlet.2018.02.033_bib44","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1182\/blood.V83.9.2560.2560","article-title":"Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects","volume":"83","author":"Sykes","year":"1994","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.canlet.2018.02.033_bib45","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1326","article-title":"Host-reactive CD8+ memory stem cells in graft-versus-host disease","volume":"11","author":"Zhang","year":"2005","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.canlet.2018.02.033_bib46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ni1580","article-title":"Natural killer cell-directed therapies: moving from unexpected results to successful strategies","volume":"9","author":"Terme","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2018.02.033_bib47","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fimmu.2015.00286","article-title":"Present and future of allogeneic natural killer cell therapy","volume":"6","author":"Lim","year":"2015","journal-title":"Front. Immunol."},{"issue":"26","key":"10.1016\/j.canlet.2018.02.033_bib48","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2015-12-629055","article-title":"Exploitation of natural killer cells for the treatment of acute leukemia","volume":"127","author":"Handgretinger","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2018.02.033_bib49","article-title":"Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia","volume":"3","author":"Rujkijyanont","year":"2013","journal-title":"Blood Canc. J."},{"key":"10.1016\/j.canlet.2018.02.033_bib50","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28497","article-title":"Secretory pathways generating immunosuppressive NKG2D ligands: new targets for therapeutic intervention","volume":"3","author":"Baraga\u00f1o Raneros","year":"2014","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.canlet.2018.02.033_bib51","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J.\u00a0Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2018.02.033_bib52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2013.085209","article-title":"Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials","volume":"99","author":"Pollyea","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.canlet.2018.02.033_bib53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2015.07.042","article-title":"Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner","volume":"368","author":"Fern\u00e1ndez","year":"2015","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.canlet.2018.02.033_bib54","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/08880018.2017.1360970","article-title":"Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia","volume":"34","author":"Messinger","year":"2017","journal-title":"Pediatr. Hematol. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518301721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518301721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T15:22:56Z","timestamp":1603898576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518301721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":54,"alternative-id":["S0304383518301721"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.02.033","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}